Bayer Links

RED AS BLOOD

Before it is approved for medical use, each and every drug candidate is rigorously tested in numerous studies. And the active ingredient rivaroxaban is no exception. As part of the registration procedure of this modern oral coagulation inhibitor, experts working at Bayer Technology Services, together with their colleagues from Bayer HealthCare, simulated the coagulation processes in blood vessels – also using a computer.

The mathematical models required for this purpose integrated data from hundreds of trials as well as from scientifically substantiated assumptions about coagulation. With the help of coagulation programs, it is possible to simulate the optimal dose range and to plan clinical studies more efficiently. More than 100,000 patients will have participated in the comprehensive program of clinical trials involving rivaroxaban by the time all the studies have been completed. This scanning electron microscope image shows elements of blood coagulation in 7,500-fold magnification: the red blood cells (erythrocytes) of a clot in a net of fibrin threads.

Quicksearch Quicksearch
technologysolutions 2010

more issues

technologysolutions 2011

more issues

technologysolutions 2012

more issues

technologysolutions 2013

more issues

technologysolution 2014

more issues